209 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author신진호-
dc.date.accessioned2017-10-17T01:49:10Z-
dc.date.available2017-10-17T01:49:10Z-
dc.date.issued2015-12-
dc.identifier.citationCLINICAL THERAPEUTICS, v. 37, NO 11, Page. 2581-2596en_US
dc.identifier.issn0149-2918-
dc.identifier.issn1879-114X-
dc.identifier.urihttp://www.sciencedirect.com/science/article/pii/S0149291815000892?via%3Dihub-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/30054-
dc.description.abstractPurpose: The objective of this study was to evaluate the efficacy and safety of a fimasartan/amlodipine combination in patients with hypertension and to determine the optimal composition for a future single-pill combination formulation. Methods: This Phase II study was conducted by using a randomized, multicenter, double-blind, placebo-controlled, 3 x 3 factorial design. After a 2-week placebo run-in period, eligible hypertensive patients (with a sitting diastolic blood pressure [SiDBP] between 90 and 114 mm Hg) were randomized to treatment. They received single or combined administration of fimasartan at 3 doses (0, 30, and 60 mg) and amlodipine at 3 doses (0, 5, and 10 mg) for 8 weeks. The primary efficacy end point was the change in SiDBP from baseline and at week 8; secondary end points included the change in SiDBP from baseline and at week 4 and the changes in sitting systolic blood pressure from baseline and at weeks 4 and 8. Treatment-emergent adverse events (AEs) were also assessed. Findings: 420 Korean patients with mild to moderate hypertension were randomly allocated to the 9 groups. Mean (SD) SiDBP changes in each group after 8 weeks were as follows: placebo, -6.0 (8.5) mm Hg; amlodipine 5 mg, -10.6 (9.2) mm Hg; amlodipine 10 mg, -15.9 (7.2) mm Hg; fimasartan 30 mg, -10.1 (9.1) mm Hg; fimasartan 60 mg, -13.0 (10.0) mm Hg; fimasartan 30 mg/amlodipine 5 mg, -16.2 (8.5) mm Hg; fimasartan 30 mg/amlodipine 10 mg, -19.5 (7.5) mm Hg; fimasartan 60 mg/amlodipine 5 mg, -16.6 (6.9) mm Hg; and fimasartan 60 mg/amlodipine 10 mg, -21.5 (8.3) mm Hg. All treatment groups produced significantly greater reductions in blood pressure compared with the placebo group. In addition, all combination treatment groups had superior reductions in blood pressure compared with the monotherapy groups. In the combination treatment groups, doubling fimasartan dose in the given dose of amlodipine did not show further BP reduction, whereas doubling amlodipine dose showed significantly further BP reduction in the given dose of fimasartan. During the study period, 75 (17.9%) of 419 patients experienced 110 AEs. Ninety-five AEs were mild, 9 were moderate, and 6 were severe in intensity. Eight patients discontinued the study due to AEs. There was no significant difference in incidence of AEs among groups (P = 0.0884). The most common AE was headache (12 patients [2.9%]), followed by dizziness (11 patients [2.6%]) and elevated blood creatine phosphokinase levels (6 patients [1.4%]). Implications: Fimasartan combined with amlodipine produced superior blood pressure reductions and low levels of AEs compared with either monotherapy. Therefore, a single-pill combination with fimasartan 60 mg/amlodipine 10 mg will be developed. (C) 2015 Elsevier HS Journals, Inc. All rights reserved.en_US
dc.description.sponsorshipThis study was sponsored by Boryung Pharmaceutical Co, Ltd. Lee HY and Jeon ES searched the previous literatures, created figures and wrote the manuscript. Jeon ES cooperated the sponsored company in designing the study. Kim YJ, Ahn T, Youn HJ, Chae SC, Seo HS, Kim KS, Rhee MY, Choi DJ, Kim JJ, Chun KJ, Yoo BS, Park JS, Oh SK, Kim DS, Kwan J, Ahn Y, Park JB, Jeong JO, Hyon MS, Cho EJ, Han KR, Kim DI, Joo SJ, Shin JH, Sung KC and Jeon ES collected and interpreted date.en_US
dc.language.isoenen_US
dc.publisherELSEVIERen_US
dc.subjectamlodipineen_US
dc.subjectangiotensin receptor blockeren_US
dc.subjectcalcium channel blockeren_US
dc.subjectfimasartanen_US
dc.subjecthypertensionen_US
dc.titleA Randomized, Multicenter, Double-Blind, Placebo-Controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertensionen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.clinthera.2015.02.019-
dc.relation.page1-15-
dc.relation.journalCLINICAL THERAPEUTICS-
dc.contributor.googleauthorLee, Hae-Young-
dc.contributor.googleauthorKim, Yong-Jin-
dc.contributor.googleauthorAhn, Taehoon-
dc.contributor.googleauthorYoun, Ho-Joong-
dc.contributor.googleauthorChae, Shung Chull-
dc.contributor.googleauthorSeo, Hong Seog-
dc.contributor.googleauthorKim, Ki-Sik-
dc.contributor.googleauthorRhee, Moo-Yong-
dc.contributor.googleauthorChoi, Dong-Ju-
dc.contributor.googleauthorShin, Jin-Ho-
dc.relation.code2015001009-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidjhs2003-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE